

# ESMO 2024&WCLC 2024亮点梳理

2024年8月14日

分析师：祝嘉琦

执业证书编号：S0740519040001

分析师：曹泽运

执业证书编号：S0740524060002

分析师：穆奕杉

执业证书编号：S0740524070001

**国产在研重磅产品动态**

**国产已上市产品的重要适应症拓展更新**

**海外重要产品数据及相关标的**

# 汇报目的

- ESMO全称为European Society of Medical Oncology（欧洲内科肿瘤学会），是全球领先的肿瘤医学专业组织。ESMO拥有来自全球168个国家30,000多名肿瘤学领域成员，深耕肿瘤学前沿进展传播和肿瘤医生教育。
- 世界肺癌大会（WCLC）是世界上最大的肺癌和其他胸部恶性肿瘤会议。来自100多个国家的7000多名代表共同探讨胸部恶性肿瘤研究的最新进展。
- 创新药产品在ESMO、WCLC发布的临床研究结果，被认为具备权威性，是注册上市乃至上市后推广的根本依据，也是在境内外完成对外授权的价值判断依据





1

# 国产在研重磅产品动态

# 标题概览-ESMO 2024 国产在研重磅产品

- BL-B01D1: 尿路上皮癌入选口头, 食管鳞癌国内大适应症, 同靶点双抗SI-B001已披露ORR=45.45% (2L+, n=11, 联合伊利替康)

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
阿诺医药	AN0025	EP4	局部晚期或局部复发食管癌(EC)	II 期	1453P	Poster	A Phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)	Nan Bi (Shenzhen, China)
安锐生物	AVZO-021	CDK2	晚期实体瘤	I期	439TIP	Poster	AVZO-021-1001: A First-in-human Open-Label, Multicenter Phase 1/2 Dose-Escalation and Expansion Study Evaluating AVZO-021 in Adult Patients With Advanced Solid Tumors	Afshin Dowlati (Cleveland, United States of America)
百吉生物	BRG01	EBV CAR-T	晚期转移性鼻咽癌	II 期	899P	Poster	Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr Virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer patients	Li Zhang (Guangzhou, China, Guangdong)
百利天恒/BMS	BL-B01D1	EGFRxHER3 ADC	UC	III 期	1959O	口头报告	BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC)	Dingwei Ye (Shanghai, China)
百利天恒/BMS	BL-B01D1	EGFRxHER3 ADC	BTC	III 期	54P	Poster	BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Biliary Tract Carcinoma (BTC)	Zhihao Lu (Beijing, China)
百利天恒/BMS	BL-B01D1	EGFRxHER3 ADC	ESCC	III 期	1426P	Poster	BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)	Liu Chang (Beijing, China)
贝达药业	泰贝西利+氟维司群	CDK4/6+SERD	HR+乳腺癌二线	III 期	320MO	口头报告	Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study	Xichun Hu (Shanghai, China)
百力司康	BB-1701	HER2 ADC	HER2突变/扩增 NSCLC	I/II 期	1296P	Poster	A phase 2 study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification	Caicun Zhou (Shanghai, China)
璧辰医药	ABM-1310	BRAF	BRAF V600 mutated 脑肿瘤	I 期	453MO	口头报告	A Phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumors: interim result	Wenbin Li (Beijing, China)
创胜集团	TST001+O药	CLDN18.2+PD-1	1L 胃癌	III 期	1419P	Poster	Osemitamab (TST001) plus Nivolumab and CAPOX as the First-line Therapy for the Patients with Advanced G/G EJ Cancer (TranStar102)	Lin Shen (Beijing, China)
辰欣药业	WX390	PI3K/mTOR	PIK3CA和ARID1A并发突变癌症	II 期	789P	Poster	Translational study and preliminary clinical trial of WX390 monotherapy in cancers with concurrence of PIK3CA and ARID1A mutations	Jiajia Li (Shanghai, China)

# 标题概览-ESMO 2024 国产在研重磅产品

- ATG-037: 国内第一款CD73小分子, 德琪已与MSD达成全球临床合作, 开发ATG-037+K药用于治疗晚期实体瘤

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
辰欣药业	WX390+特瑞普利单抗	PI3K/mTOR+PD-1	复发或转移性头颈部鳞状细胞癌	II 期	874P	Poster	Preliminary Outcomes from a Phase 1b/2 Study of WX390 Combined with Toripalimab in Patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma	Ye Guo (Shanghai, China)
德琪医药	ATG-037±K药	CD73+PD-1	晚期实体瘤	I 期	997MO	口头报告	A First-In-Human Phase I/Ib study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Advanced Solid Tumors - STAMINA-01	Ganessan Kichenadasse (Adelaide, Australia)
复诺健生物	VG2025	IL-12 and IL-15/Rα 溶瘤病毒	晚期实体肿瘤	I 期	994MO	口头报告	The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors	Yinan Shen (Hangzhou, China)
高诚生物	HFB200301±替雷利珠单抗	TNFR2 agonist mAb+PD-1	晚期实体瘤	I 期	1011P	Poster	Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors.	Desamparados Roda Perez (Valencia, Spain, Valencia)
高诚生物	HFB200603±替雷利珠单抗	BTLA antagonist mAb + PD1	晚期实体瘤	I 期	1006P	Poster	Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb Tislelizumab (TIS) in adult patients (pts) with advanced solid tumors.	María De Miguel (Madrid, Spain)
恒瑞医药	SHR-A1904	CLDN18.2 ADC	GC/GEJC	I/II 期	609O	口头报告	CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study	Rui-Hua Xu (Guangzhou, China, Guangdong)
恒瑞医药	SHR-A1811+吡咯替尼	HER2 ADC+EGFR/HER2	HER2+BC新辅助	III 期	276P	Poster	SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2 positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07	Cai G. Liu (shenyang, China)
恒瑞医药	SHR-A2009	HER3 ADC	EGFR-mutated NSCLC	II 期	642P	Poster	Phase 1 study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC	Qing Zhou (Zhanjiang, China)
恒瑞医药	SHR-A2102	nectin-4 ADC	晚期实体瘤	I/II 期	649P	Poster	Phase 1 study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors	Hua Zhong (Shanghai, China)

# 标题概览-ESMO 2024 国产在研重磅产品

- SHR-A1921: 用于治疗铂耐药复发上皮性卵巢癌、输卵管癌及原发性腹膜癌已获FDA FTD, 针对铂耐药卵巢癌TROP2 ADC治疗方案数据读出稀少
- HBM1020: B7H7赛道玩家稀少, 此品种已获批FDA IND

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
恒瑞医药	SHR-1701	PD-L1/TGF-βRII	1L胰腺癌	III 期	1526P	Poster	Anti-PD-L1/TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine in previously untreated patients with locally advanced or metastatic pancreatic cancer: a multicenter, phase 1b/2 study	Jiajia Yuan (Beijing, China)
恒瑞医药	SHR-A1921	TROP2 ADC	PROC	III 期	717MO	口头报告	SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase 1 study	Dihong Tang (Changsha, China)
恒瑞医药	SHR-A1921	TROP2 ADC	NSCLC	III 期	1310P	Poster	SHR-A1921, a trophoblast cell-surface antigen 2 (TROP-2) targeted antibody-drug conjugate (ADC), for the treatment of advanced NSCLC	Jie Wang (Beijing, China)
恒瑞医药	达尔西利	CDK4/6	HR+/HER2-BC新辅助	II 期	244P	Poster	Efficacy and Safety of Dalpiciclib, Exemestane, and Goserelin as Neoadjuvant Therapy in Premenopausal HR-positive, HER2-negative Breast Cancer Patients: A Phase 2 Clinical Trial	Yang Zhengjun (Tianjin, China)
和铂医药	HBM1020	B7H7	晚期实体瘤	I 期	1010P	Poster	Ph I Dose Escalation Study of HBM1020, a Novel Anti-B7H7 Antibody in Patients with Advanced Solid Tumors	Jason Henry (Nashville, United States of America)
和誉医药/AZ	AZD4547	Pan-FGFR	FGFR+肿瘤	II 期	1015P	Poster	The efficacy and mechanism of Pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors	Qizhi Ma (Chengdu, China)
和誉医药	ABSK-011	FGFR4	肝癌	II 期	983P	Poster	Updated Safety and Efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF 19 overexpression from a Phase 1 study	Xiao-Ping Chen (Wuhan, China)
海正药业	ZV0203	HER2 ADC	HER2+晚期实体瘤	I 期	335P	Poster	First-in-human phase 1/2a clinical trial of ZV0203, a novel petuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors	Fengjuan Lin (Shanghai, China)

# 标题概览-ESMO 2024 国产在研重磅产品

- Afuresertib: 国内进度第一梯队, 阿斯利康同类品种针对乳腺癌已充分验证成药性, 2023 SABCS公布了Afuresertib联合氟维司群治疗HR+/HER2-乳腺癌患者的1b期研究数据: ORR=30%, DCR=80%, mPFS为7.3个月

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
加科思	JAB-2485	Aurora-A	实体瘤	II期	689TiP	Poster	A phase 1/2a trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors.	Vaia Florou (Salt Lake City, United States of America)
加科思	Glecirasib+JAB-3312	KRAS G12C+SHP2	一线NSCLC	NDA	1261P	Poster	Efficacy of Glecirasib in Combination with JAB-3312 as a Front-line Treatment for Patients with KRAS p.G12C mutated NSCLC with PD-L1 Expression Levels or Co-mutations.	Jie Wang (Beijing, China)
嘉和生物	GB263T	EGFR/cMET/cMET	EGFRm NSCLC	I/II 期	1272P	Poster	Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)	Jin-Ji Yang (Guangzhou, China, Guangdong)
康宁杰瑞	JSKN003	HER2双抗ADC	卵巢癌	III 期	759P	Poster	JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer. A pooled analysis of two studies.	Qunxian Rao (Guangzhou, China)
康宁杰瑞	KN026	HER2双抗	曲妥珠经治GE/GEJC	III 期	1425P	Poster	Efficacy and safety of KN026 in combination with chemotherapy in patients (pts) with unresectable or metastatic HER2 positive gastric or gastroesophageal cancers (GC/GEJC) after first-line treatment with a trastuzumab-containing regimen	Jianming Xu (Beijing, China)
来凯医药	Afuresertib+氟维司群	AKT+SERD	经治HR+/HER2-乳腺癌	III 期	370P	Poster	A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Subjects with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies: A Subgroup Analysis of Efficacy in PIK3CAAKT1/PTEN-Altered Subjects	Pin Zhang (Beijing, China)
科伦博泰	EP0031	RET	RET改变阳性实体瘤	I/II 期	1295P	Poster	EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naive to or following prior SRI	Elena Garralda (Barcelona, Spain)

# 标题概览-ESMO 2024 国产在研重磅产品

- SKB264: 两项口头多项Poster同步汇报, 多癌种研发进度强势并进 (其中国内研究三项, 海外已授权MSD, 本次3项3期)

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
科伦博泰/MSD	SKB264	TROP2 ADC	经治TNBC是否免疫经治分析	上市申请	386P	Poster	Exploratory Analysis of Patients With or Without Prior PD-(L)1 Inhibitors in Phase III OptiTROP-Breast01 study of Sacituzumab Tirumotecan (sac-TMT) Versus Chemotherapy for Previously Treated Advanced Triple-Negative Breast Cancer (TNBC)	Yongmei Yin (Nanjing, China, Jiangsu Province)
科伦博泰/MSD	SKB264	TROP2 ADC	经治子宫内膜癌	上市申请	793TiP	Poster	A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT) Monotherapy vs Treatment of Physician' s Choice Chemotherapy in Patients With Endometrial Cancer Who Have Received Prior Chemotherapy and Immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005	Domenica Lorusso (Milan, Italy)
科伦博泰/MSD	SKB264±K药	TROP2 ADC±PD-1	HR+/HER2- BC	上市申请	433TiP	Poster	Phase 3, Randomized, Open-label TroFuse-010 Study of Sacituzumab Tirumotecan (sac-TMT) Alone and With Pembrolizumab vs Treatment of Physician' s Choice Chemotherapy (TPC) in Patients With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (mBC)	Sara M. Tolaney (Boston, United States of America, MA)
科伦博泰/MSD	SKB264	TROP2 ADC	经治食管腺癌	上市申请	1471TiP	Poster	MK-2870-015: A phase 3 study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician' s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)	Zev A. Wainberg (Los Angeles, United States of America)
科伦博泰/MSD	SKB264	TROP2 ADC	经治子宫内膜癌和卵巢癌	上市申请	715MO	口头报告	Safety and Efficacy of Sacituzumab Tirumotecan (sac-TMT) in Patients (pts) with Previously Treated Advanced Endometrial Carcinoma (EC) and Ovarian Cancer (OC) from a Phase 2 Study	Danbo Wang (Shenyang, China)
科伦博泰/MSD	SKB264+K药	TROP2 ADC+PD-1	宫颈癌	上市申请	716MO	口头报告	Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT) Plus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer	Jing Wang (Changsha, China)
乐普生物	MRG002+普特利单抗	HER2 ADC+PD-1	UC	III 期	1990P	Poster	MRG002-HER2 ADC combined with Pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study	Chuanliang Cui (Beijing, China)
明济生物	FG-M108	CLDN18.2	CLDN18.2+胰腺癌	I/II 期	1530P	Poster	preliminary result of a phase Ib study: efficacy and safety of FG-M108 plus gemcitabine and nab. paclitaxel in patients with Claudin18.2 positive locally advanced unresectable or metastaticpancreatic cancer	Funan Liu (Nanjing, China)
普米斯 /BioNTech	PM8002	PD-L1/VEGF	1L TNBC	III 期	348MO	口头报告	A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-negative Breast Cancer	Jiong Wu (Shanghai, China)
普米斯 /BioNTech	PM8002	PD-L1/VEGF	EGFR突变NSCLC	III 期	1255MO	口头报告	A Phase II Safety and Efficacy Study of PM8002/BNT-327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)	Yi-Long Wu (Guangzhou, China, Guangdong)
普米斯/BioNTech	PM8002	PD-L1/VEGF	晚期肾细胞癌	III 期	1692P	Poster	A Phase Ib/IIa Trial to Evaluate the Safety and Efficacy of PM8002/BNT327, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients with advanced renal cell carcinoma	Xinan Sheng (Beijing, China)

# 标题概览-ESMO 2024 国产在研重磅产品

- Givastomig: 全球首款CLDN18.2/41BB双抗, 在ESMO 2023首次读出数据, 安全性佳(各类G3及以上TRAE < 2%), MTD未达到, 针对CLDN18.2+泛瘤种, 疗效初显(3/20, 3名均在8w时PR)

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
齐鲁制药	QL1706	PD-1&CTLA-4鸡尾酒	局部晚期食管鳞状细胞癌	申请上市	1414P	Poster	Iparomlimab and tuvonorlimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: an open-label phase II study	Wencheng Zhang (Tianjin, China)
荣昌生物	RC118	CLDN18.2 ADC	晚期胃/食管交界处癌	II 期	1456P	Poster	First in Human Phase I/II Trial of Claudin 18.2 ADC RC118 in Patients with Advanced Gastric/Gastroesophageal Junction Cancer	Tianshu Liu (Shanghai, China, Changning)
荣瑞医药	OVV-01	溶瘤病毒	晚期实体肿瘤	II 期	993MO	口头报告	A phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors	Yingqi Hua (China, China)
石药集团	SYHA1813	VEGFR/CSF1R	复发胶质母细胞瘤	II 期	446MO	口头报告	SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma	Wenbin Li (Beijing, China)
上海医药/亦诺微	T3011	IL-12+PD-1抗体溶瘤病毒	BCG经治NMIBC	I 期	1998P	Poster	Preliminary Results From a Phase I Study of T3011, an Oncolytic HSV Expressing IL-12 and Anti-PD-1 Antibody, for BCG-Failure Non-Muscle-Invasive Bladder Cancer (NMIBC)	Dingwei Ye (Shanghai, China)
诗健生物	ESG401	TROP2 ADC	HER2-转移性乳腺癌	III 期	349MO	口头报告	Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer	Fei Ma (Beijing, China)
天士力	TSL-1502	PARP	Germline BRCA突变BC	II 期	393P	Poster	A phase II Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations	Bo Lan (Beijing, China)
天境生物	Givastomig	CLDN18.2/4-1BB	CLDN18.2+食管癌	I 期	1017P	Poster	Updated Safety and Efficacy from the Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Claudin 18.2 Positive Advanced Gastroesophageal Carcinoma (GEC)	Samuel J. Klemptner (Boston, United States of America, CA)
同宜医药	CBP-1008	TRPV6/FR $\alpha$	晚期实体瘤	II/III 期	787P	Poster	First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors	Ning Li (Beijing, China)
同宜医药	CBP-1018	PSMA/FR $\alpha$	前列腺癌(mCRPC)	II/III 期	1602P	Poster	CBP-1018, Bi-Ligand-Drug Conjugate (Bi-XDC) Drug Treated for Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients from Phase I Study Results	Kaiwen Li (Guangzhou, China)
同宜医药	CBP-1019	TRPV6/FR $\alpha$	晚期实体瘤	II/III 期	648P	Poster	An Open-Label, MRCT Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of First-in-Class Bi-Ligand-Drug Conjugate CBP-1019 in Patients (pts) with Advanced Solid Tumors	Dan Liu (Beijing, China)

# 标题概览-ESMO 2024 国产在研重磅产品

- IBI363: 曾展现针对CRC单药亮眼数据, 83.8%MSS/pMMR, 76.5%既往≥3线系统治疗, 61.8%肝转, 中位随访5.3m, 在PD-L1 CPS≥1受试者中, ORR为30.8%, DCR为76.9%, 此次贝伐combo研究值得期待, 此外该产品具跨瘤种潜力, 针对NSCLC、黑色素瘤均有积极数据读出

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
信达生物	IBI354	HER2 ADC	晚期实体瘤和乳腺癌	I/II 期	345MO	口头报告	IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): results from a phase I study	Charlotte Lemech (Randwick, Australia)
信达生物	IBI354	HER2 ADC	晚期妇科癌症	I/II 期	720MO	口头报告	IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): results from a phase 1 study	Jin Shu (Chongqing, China)
信达生物	IBI354	HER2 ADC	晚期胃肠道(GI)癌	I/II 期	576P	Poster	Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: results from a phase 1 study	Jifang Gong (Beijing, China)
信达生物	IBI363+贝伐珠单抗	PD-1/IL-2+VEGF	晚期CRC	II 期	574P	Poster	First-in-class PD-1/L-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study	Zhen Yu Lin (Wuhan, China)
宜明昂科	IMM01	CD47	一线CMML	III 期	801MO	口头报告	Efficacy and Safety of a Phase 2 Study: Timdarpacept (IMM01) Combined with Azacitidine (AZA) As the First-Line Treatment in Adults with Chronic Myelomonocytic Leukemia (CMML)	Hongyan Tong (Hangzhou, China)
宜明昂科	IMM01	CD47	免疫经治经典霍奇金淋巴瘤	III 期	809MO	口头报告	Efficacy and safety results from the phase 2 study of Timdarpacept in combination with tilizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma	Yuqin Song (Beijing, China)
宜明昂科	IMM2520	CD47/PD-L1	实体瘤	I期	662P	Poster	A phase 1 study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor	Yuping Sun (Jinan, China)
宜明昂科	IMM0306	CD20/SIRPα	R/R CD20+B-NHL	I/II 期	822P	Poster	Preliminary Results from a Phase Ib Study of Amulirafusp alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-positive B-cell non-Hodgkin's lymphoma	Lijuan Deng (Beijing, China)
宜明昂科	IMM0306	CD20/SIRPα	非霍奇金淋巴瘤	I/II 期	839P	Poster	Preliminary Results from a Phase II Study of Amulirafusp alfa (IMM0306) in Patients with Relapsed or Refractory CD20-positive B-cell non-Hodgkin's lymphoma	Jianliang Yang (Beijing, China)
宜联生物	YL201	B7H3 ADC	晚期实体肿瘤	II 期	605O	口头报告	YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase 1 study	Hongyun Zhao (Guangzhou, China)

# 标题概览-ESMO 2024 国产在研重磅产品

- Rovadicitinib: 小赛道少竞争新领域, 关注输血依赖、脾环节等、长期有效性等多个指标;
- ZG006: 全球FIC产品

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
应世生物	Ifebemtinib	FAK	KRAS G12C Mutation实体瘤	II期	622P	Poster	Safety and Efficacy of Ifebemtinib (IN10018) Combined with D-1553 in Solid Tumors with KRAS G12C Mutation: Results from a Phase Ib/II Study	Zhengbo Song (Hangzhou, China)
友芝友	M701	EpCAM x CD3	NSCLC	III期	1371P	Poster	An Ani-EpCAM x CD3 Bispecific Antody, M701, for the Treatment of Malignant Pleura Effusion in NSCLC Patients: Interim Results of a Prospective Multicenter Phase Ib Trial	Jun Cai (Jingzhou City, China)
正大天晴	rovadicitinib	JAK/ROCK	骨髓纤维化	申请上市	799MO	口头报告	The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis	Ling Pan (Chengdu, China)
正大天晴	TQB3909	BCL-2	非霍奇金淋巴瘤和急性髓性白血病	II期	800MO	口头报告	First Report of BCL-2 Inhibitor TQB3909 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML): Data From a Phase I Study	Junyuan Qi (Tianjin, China)
正大天晴	AL2846	MET	甲状腺癌	III期	1927P	Poster	AL2846 in patients (pts) with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) previously treated with tyrosine kinase inhibitors (TKI): Preliminary clinical results from the phase Ib study.	Feng Shi (Changsha, China)
正大天晴	TQB3616	CDK2/4/6	去分化脂肪肉瘤	申请上市	1731P	Poster	Phase II study of the CDK2/4/6 Inhibitor TQB3616 capsules in patients with dedifferentiated liposarcomas (DDLPS)	Jing Chen (Wuhan, China)
再鼎医药	ZL-1218	CCR8	晚期实体瘤	I期	1008P	Poster	Preliminary Clinical PK and PD analysis of a Phase 1 Study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors	Ignacio Gil Bazo (Valencia, Spain)
泽璟制药	ZG006	三抗	SCLC、神经内分泌肿瘤	I期	686TiP	Poster	Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinoma.	QiMing Wang (Zhengzhou, China)
智康弘义	BC3195	CDH3 ADC	晚期实体瘤	I期	1315P	Poster	BC3195, a Novel ADC Targeting CDH3: Preliminary Results of a First-in Human Phase I Study in Patients with Advanced Solid Malignancies	Hua-Jen Chen (Guangzhou, China)

# 标题概览-WCLC 2024国产在研重磅产品

- SKB264: 三个NSCLC细分适应症海外3期; IBI363: 大适应症NSCLC前期数据优秀, 本次入选口头期待再度经验

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
鞍石生物	vebreltinib+安达替尼	MET+EGFR	MET+EGFR TKI经治NSCLC	上市, III期	MA12.03	口头报告	Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI	W. Li, Department of Oncology, Shanghai Pulmonary Hospital, Shanghai/CN
贝达药业	MRX-2843+奥希替尼	MERTK / FLT3+EGFR	EGFR Mutant NSCLC	I/II期	P1.12A.09	poster	A Phase 1b Study of the MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination with Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer	C. Steuer, Winship Cancer institute of Emory University, atlanta/GA/USA
百济神州	替雷利珠单抗+司曲替尼	PD-1+RET、KDR、PDGFRA、KIT、TRK、DDR2、MET、AXL和CBL等	免疫及化疗经治NSCLC	上市, III期	OA06.03	口头报告	SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1.	Y-L. Wu (Guangdong Provincial People's Hospital)
翰森制药	HS-20093	B7H3 ADC	小细胞肺癌	I期	OA04.06	口头报告	Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)	J. Wang
恒瑞医药	HRS-4642	KRAS G12D	KRAS G12D突变肿瘤	一/二期	P3.12E.03	poster	Anti-Tumor Efficacy of HRS-4642 and its Potential Combination with Proteasome Inhibition in KRAS G12D-Mutant Cancer	L. Luo (Shanghai Hengrui Pharmaceutical Co., Ltd.)
恒瑞医药	SHR-1701+氟唑帕利	PDL1/TGFβ+PARP	SCLC维持治疗	III期	MA11.07	口头报告	Preliminary Efficacy and Safety of SHR-1701 Plus Fluzoparib as Maintenance Therapy for Patients with Advanced Lung Squamous Cell Carcinoma.	Y. Zhang (Hunan Cancer Hospital)
恒瑞医药	SHR-A1921	TROP2 ADC	小细胞肺癌	III期	OA04.05	口头报告	SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate(ADC), In Patients(pts) with Advanced Small-Cell Lung Cancer(SCLC).	J. Wang (Chinese Academy of Medical Sciences and Peking Union Medical College)
君实生物	Tifcemalimab+Toripalimab	BTLA单抗	ES-SCLC	III期	MA17.08	口头报告	Safety and Efficacy of Tifcemalimab Combined with Toripalimab in Refractory Extensive Stage Small Cell Lung Cancer	Y. Cheng, Jilin Cancer Hospital, Changchun/CN
科伦博泰	SKB264	TROP2 ADC	经治EGFRm NSCLC	上市申请	P2.10A.07	poster	Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC	N.B. Leighl, Princess Margaret Cancer Centre, University of Toronto, Toronto/ON/CA
科伦博泰	SKB264	TROP2 ADC	经治EGFR或其他基因突变NSCLC	上市申请	P2.10A.06	poster	Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations	E.B. Garon (Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of N. Frost (Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate
科伦博泰	SKB264	TROP2 ADC	1L PD-L1+ NSCLC	上市申请	P4.11D.02	poster	Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50%	Q. Zhou (Guangdong Provincial People's Hospital)
信达生物	IBI351	KRAS G12C	NSCLC	申请上市	OA14.03	口头报告	KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study.	J. Zhou (The First Affiliated Hospital, Zhejiang University School of Medicine)
信达生物	IBI363	PD-1/IL-2	NSCLC	II期	MA11.03	口头报告	First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study.	L. Wu, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha/CN
正大天晴	TQB2618+AK105	TIM-3+PD-1	NSCLC	II期, 上市	MA11.11	口头报告	A Phase Ib Study of TQB2618 (Anti-TIM-3) in Combination with Penpulimab and Chemotherapy in Patients with Non-Small Cell Lung Cancer	D. Huang, Tianjin Medical University Cancer Institute & Hospital, Tianjin/CN
正大天晴	AL2846+贝莫苏拜单抗	CMET+PD-L1	PD-(L)1经治NSCLC	III期, 上市	P4.11E.03	poster	Safety and Efficacy of AL2846 Combined with TQB2450 In NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)	

## 重点关注：IBI363-考虑患者基线（MSS、肝转、线数），治疗CRC ORR优越

Table 1. Immune checkpoint inhibitor monotherapy or dual immune checkpoint inhibitors.

Clinical trial identifier/ study title	Treatment line	Treatment scheme	Sample size (n)	Phase/ (randomization)	ORR	DCR	mPFS (months)	mOS (months)	Additional comments
NCT03981146/ ANICCA <sup>22</sup>	N/A (No SOC option and had tumors with >1% tsMHC-II)	Nivolumab	35	2	0%	8.6%	9.1 weeks	29.6 weeks	The proportion of patients with liver metastases on nivolumab for 18 weeks and beyond was 9%, while this rate was 38% in patients without liver metastases. The rate for tsMHC-II-positive tumors was 13% in screened patients with MSS CRC
NCT03860272 <sup>23</sup>	≥1 prior line of treatment	Botensilimab + baltimab	59	1	22%	73%	4.1	NR (12-month OS rate 61%)	The benefit persisted in the updated data. The updated data from the World GI Congress (n = 87): ORR in patients without liver mets 23%, ORR in patients with liver mets 0%
NCT02870920/ The Canadian Cancer Trials Group CO.26 Study <sup>24</sup>	All patients had received multiple lines of prior chemotherapy	Tremelimumab + durvalumab Best supportive care alone (BSC)	119 61	2 (2:1)	1.2% 0%	22.7% 6.6%	1.8 1.9	6.6 4.1	Grades 3-4 AEs in 64% of the patients treated with ICIs Patients with plasma TMB of 28/Mb or higher (21% of the patients with MSS CRC) had OS benefit (HR: 0.34, 90% CI: 0.18-0.63)
NCT01876511/ KEYNOTE-016 <sup>11</sup>	≥ 2 previous lines of chemotherapy	Pembrolizumab	18	2	0%	11%	2.2	5	
NCT02060188/ CheckMate 142 <sup>12</sup>	≥1 prior line of treatment	Nivolumab	23	2	N/A	N/A	1.4	N/A	
NCT05460767	76.5%的受试者既往接受过≥3线系统治疗	IBI363单药100μg/kg QW 至3mg/kg Q3W	68接受治疗	1	所有剂量组ORR为12.7%；1mg/kg剂量组的ORR为15.0%；在PD-L1 CPS≥1的13例受试者中，ORR为30.8%	在PD-L1 CPS≥1的13例受试者中，DCR为76.9%	\	\	83.8%的受试者为MSS/pMMR，其余受试者MMR状态未知；61.8%的受试者在基线时存在肝转移

## 重点关注：SKB264-后线、一线 PD-L1+NSCLC疗效媲美Dato

药品代码	公司名称 (受让方/出让方)	靶点	药物类型	首发时间	最后发表	阶段	入组患者	入组患者标签	例数N	ORR	
										实验组	对照组
SKB264	科伦博泰	TROP-2	ADC	2023年6月	2023ASCO	1/2期	经治NSCLC: TROP2-ADC 5mg/kg Q2w	后线	43	wt: 26% EGFR+: 60%	单臂
DS1062	阿斯利康/第一三共	TROP-2	ADC	2023年6月	2023ASCO	1期	PD-L1无筛选, NSCLC (一线亚组): Dato + K药 ± 铂二联	后线	42	D+K+化疗: 29% D+K: 24%	单臂

药品代码	公司名称 (受让方/出让方)	靶点	药物类型	首发时间	最后发表	阶段	入组患者	入组患者标签	例数N	ORR	
										实验组	对照组
DS1062	阿斯利康/第一三共	TROP-2	ADC	2023年6月	2023ASCO	1期	PD-L1无筛选, NSCLC (一线亚组): Dato + K药 ± 铂二联	一线	33	D+K+化疗: 50% D+K: 62%	单臂
SKB264	MSD/科伦博泰	TROP-2	ADC	2024年6月	2024ASCO	2期	AGA-, NSCLC 1L 1A队列: SKB264 5mg/kg Q3W + KL167 (PD-L1) 1200mg Q3W 1B队列: SKB264 5mg/kg Q2W + KL167 (PD-L1) +900mg Q2W	一线	40入组1A, 63入组1B	48.6% (A队列) 77.6% (B队列)	单臂



2

# 国产已上市产品的重要适应症拓展更新

# 标题概览-ESMO 2024 国产已上市产品

## ● 舒沃替尼：国际多中心悟空1B的海外site研究入选

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
迪哲医药	舒沃替尼	EGFR ex20ins抑制剂	EGFR20ins二线	上市	1260P	Poster	Efficacy and Safety of Sunvozertinib in Prior Platinum Treated NSCLC Patients with EGFR Exon 20 Insertion Mutations: Primary Analysis from the Multinational WU- KONG1B Pivotal Study	Ludovic Doucet (Angers, France)
恒瑞医药	卡瑞利珠单抗	PD-1单抗	1L胆道癌	已上市	50P	Poster	Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC)	Yunxin Lu (Guangzhou, China)
恒瑞医药	卡瑞利珠单抗	PD-1单抗	外胆管/胆囊癌	已上市	51P	Poster	A Phase II Trial of Camrelizumab in Combination with Hepatic Arterial Infusion Chemotherapy (HAIC) for initially unresectable advanced extrahepatic cholangiocarcinoma (eCCA) and gallbladder cancer (GBC): An Interim Report	Long Yu (Zhengzhou, China)
恒瑞医药	卡瑞利珠单抗	PD-1单抗	R/M HNSCC	已上市	875P	Poster	A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)	Dongmei Ji (Shanghai, China)
恒瑞医药	卡瑞利珠单抗	PD-1单抗	食管鳞癌新辅助	已上市	1440P	Poster	Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): a single-arm, open-label, phase 2 trial	Chao Cheng (Guangzhou, China, Guangdong)
恒瑞医药	卡瑞利珠单抗	PD-1单抗	1L寡转移食管鳞癌	已上市	1452P	Poster	Camrelizumab plus chemotherapy combined with Consolidative Radiotherapy as first-line treatment for Oligometastatic Esophageal Squamous Cell Carcinoma (ESCORT-1ST-RT): a single-arm, open-label, phase 2 trial	Wei Huang (Jinan, China)
恒瑞医药	卡瑞利珠单抗+阿帕替尼	PD-1单抗+VEGF	甲状腺癌	已上市	1928P	Poster	Camrelizumab plus apatinib mesylate in patients with recurrent or metastatic poorly differentiated thyroid carcinoma (PDTC) /anaplastic thyroid carcinoma (ATC): a prospective, open-label, phase II study	Jun Cao (Hangzhou, China)
恒瑞医药	达尔西利	CDK4/6	hpv阴性, 抗pd-1耐药R/M HNSCC	上市	881P	Poster	Cetuximab with dalpicilib in patients with HPV-negative, anti-PD-1 resistant R/M HNSCC	Ju Houyu (Shanghai, China)
恒瑞医药	卡瑞利珠单抗+达尔西利	CDK4/6	抗pd-1复发或转移性难治性鼻咽癌	上市	892P	Poster	Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma	Xi Ding (Guangzhou, China)

# 标题概览-ESMO 2024 国产已上市产品

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
和黄医药	呋喹替尼	VEGFR1/2/3	转移性结直肠癌有无肝转	上市	520P	Poster	Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase 3 FRESCO-2 trial	Rocio Garcia-Carbonero (Madrid, Spain)
和黄医药	呋喹替尼	VEGFR1/2/3	转移性结直肠癌年龄分析	上市	526P	Poster	Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age	Maria Elena Elez Fernandez (Barcelona, Spain)
和黄医药	呋喹替尼+替雷利珠单抗+放疗	VEGFR1/2/3	转移性结直肠癌	上市	537P	Poster	Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single -arm, prospective phase II trial (RIFLE)	Yajie Chen (Shanghai, China)
和黄医药	呋喹替尼+特瑞普利单抗+放疗	VEGFR1/2/3	直肠癌新辅助	上市	570P	Poster	A phase II clinical study of fruquintinib (Fru) combined with toripalimab (Tor) and short-course radiotherapy (SCRT) as neoadjuvant therapy for locally advanced rectal cancer (LARC)	Ye Chen (Chengdu, China)
和黄医药	呋喹替尼+信迪利单抗+化疗	VEGFR1/2/3	1L EGFR和alk阴性nsq-NSCLC	上市	1329P	Poster	Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results	Pei Ma (Nanjing, China)
和黄医药	呋喹替尼	VEGFR1/2/3	肝转移PDAC	上市	1529P	Poster	Fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study	Miaoyan Wei (Shanghai, China)
和黄医药	呋喹替尼	VEGFR1/2/3	转移性软组织肉瘤	上市	1743P	Poster	A phase II study of Fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma	Zhiguo Luo (Shanghai, China)
和黄医药	呋喹替尼+信迪利单抗+化疗	VEGFR1/2/3	1L胃癌	上市	1475TiP	Poster	Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase 1b/2 clinical trial (FUNCTION)	Bei-Bei Chen (Zhengzhou, China)

# 标题概览-ESMO 2024 国产已上市产品

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
和黄医药	索凡替尼	VEGFR/FGFR1/CSF1R	肝癌三线	上市	974P	Poster	Surufatinib combined with ant-PD-1/PD-L1 antihody in the second line or monotherapy in third line treatment of advanced hpatacelllar carcinoma: Asigle-am, open-label, multi-center phase II study	Fuxiang Zhou (Wuhan, China, Hubei)
和黄医药	索凡替尼	VEGFR/FGFR1/CSF1R	神经内分泌肿瘤	上市	1155P	Poster	Updated results of Surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a prospective, randomized, controlled trial	Dan Cao (Chengdu, China)
和黄医药	索凡替尼	VEGFR/FGFR1/CSF1R	非鳞NSCLC	上市	1345P	Poster	Surufatinib plus toripalimab combined with pemetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial	Wen Feng Fang (Guangzhou, China)
和黄医药	索凡替尼	VEGFR/FGFR1/CSF1R	软组织肉瘤	上市	1740P	Poster	Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients faild with anthracyclines chemotherapy or monotherapy post-anlotinib progression: a multi-center, phase II trial	Yuhong Zhou (Shanghai, China, Changning)
翰森制药	氟马替尼	BCR-ABL	PH+急性淋巴细胞白血病	上市	829P	Poster	Flumatinib combined with chemotherapy for newly diagnosed adult with Ph-positive acute lymphoblastic leukemia: a single-center, retrospective observational study	HAN SHUYU (Zhengzhou, China)

# 标题概览-ESMO 2024 国产已上市产品

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
康方生物	依沃西单抗	PD-1/VEGF	三阴性乳腺癌	上市	347MO	口头报告	The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)	Xiaojia Wang (Hangzhou, China)
康方生物	卡度尼利单抗	PD-1/CTLA-4	局部进展期GC/GEJC	上市	1455P	Poster	Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial	Pengfei Zhang (Chengdu, China)
康方生物	卡度尼利单抗	PD-1/CTLA-4	晚期胆道癌	上市	52P	Poster	Cadonilimab in combination with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A Phase II, Single-arm Clinical Trial.	Ji Ma (Chengdu, China)
康方生物	卡度尼利单抗	PD-1/CTLA-4	晚期卵巢癌新辅助	上市	760P	Poster	Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trial	Jie Tang (Changsha, China)
康方生物	卡度尼利单抗	PD-1/CTLA-4	头颈部鳞状细胞癌围术期	上市	866P	Poster	Neoadjuvant and Adjuvant AK104 in patients with recurrent, resectable squamous cell carcinoma of the head and neck: A phase II study	Lei Liu (Chengdu, China, Sichuan)
康方生物	卡度尼利单抗	PD-1/CTLA-4	抗PD-1耐药复发或转移鼻咽癌	上市	893P	Poster	Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II clinical trial	Yao-Fei Jiang (Guangzhou, China)
康方生物	依沃西单抗	PD-1/VEGF	一线mCRC	上市	514P	Poster	The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as firstline (1L) treatment for metastatic colorectal cancer (mCRC)	Yanhong Deng (Guangzhou, China, Guangdong)
康方生物	依沃西单抗	PD-1/VEGF	一线PD-L1阳性R/M HNSCC	上市	876P	Poster	Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)	Xiaozhong Chen (Hangzhou, China, Zhejiang)
诺诚健华	奥布替尼	BTK	慢性淋巴细胞白血病	上市	840P	Poster	Orelabrutinib-based regimens in chronic lymphocytic leukemia with comorbidities: a real-world study	Xun Lai (Kunming, China)
诺诚健华	奥布替尼+奥妥珠单抗	BTK+CD20	边缘区淋巴瘤	上市	815MO	口头报告	A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naive marginal zone lymphoma (MZL): preliminary analysis on efficacy and safety	Jia-Dai Xu (Shanghai, China)
齐鲁制药	伊鲁阿克	ALK	ALK TKI-naive局部晚期或转移性ALK+非小细胞肺癌(NSCLC)	上市	1278P	Poster	Update of the INSPIRE study: iruplankib versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)	Yuan-Kai Shi (Beijing, China)

# 标题概览-ESMO 2024 国产已上市产品

## ● 维迪西妥单抗：海外site研究入选

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
荣昌生物	维迪西妥单抗+K药	HER2 ADC+PD-1	1L HER2+尿路上皮癌	上市	1967MO	口头报告	Preliminary Efficacy And Safety Of Disitamab Vedotin (DV) With Pembrolizumab (P) In Treatment (Tx)-Naive HER2-Expressing, Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): RC48G001 Cohort C	Matthew D. Galsky (New York, United States of America)
荣昌生物	维迪西妥单抗	HER2 ADC	HER2 Low-expressing Breast Cancer	上市	317TiP	Poster	A Randomized, Multicenter, Open-Label Phase II Neoadjuvant Study to Evaluate the Safety and Efficacy of HER2-ADC Disitamab Vedotin in Combination Toripalimab or Sequence Chemotherapy in Participants With HR-negative, HER2 Low-expressing Breast Cancer	Zhimin Shao (Shanghai, China)
荣昌生物	维迪西妥单抗	HER2 ADC	转移性乳腺癌	上市	384P	Poster	Disitamab vedotin (RC48) for previously treated HER2-expressing metastatic breast cancer with abnormal activation of PAM pathway: Results from a single-arm, prospective phase II clinical trial	Yun Wu (Beijing, China)
荣昌生物	维迪西妥单抗	HER2 ADC	胃癌新辅助	上市	1467P	Poster	Efficacy and safety of Disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of lcall advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study	Jie Chai (Jinan, China)
荣昌生物	维迪西妥单抗	HER2 ADC	胃癌	上市	1474TiP	Poster	A randomized phase 2 study of Disitamab Vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)	Ziyu Li
荣昌生物	维迪西妥单抗	HER2 ADC	转移性尿路上皮癌	上市	1979P	Poster	Disitamab vedotin (DV) plus Toripalimab (T) in unresectable lcall advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study	Li Zhou (Beijing, China)
荣昌生物	维迪西妥单抗	HER2 ADC	膀胱癌	上市	1984P	Poster	Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle- -invasive bladder cancer. A multi-center, single-arm, phase II trial	Chu Yang (Wuhan, China)
荣昌生物	维迪西妥单抗	HER2 ADC	膀胱癌	上市	2002P	Poster	Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study	Luzhe Yan (Changsha, China)
荣昌生物	维迪西妥单抗	HER2 ADC	尿路肿瘤	上市	2009P	Poster	PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)- defined clinical complete response (cCR) MIBC patients	Bin Huang (Guangzhou, China)
荣昌生物	维迪西妥单抗	HER2 ADC	宫颈癌	上市	794TiP	Poster	Disitamab Vedotin and Zimberelimab combined with Stereotactic Body Radiation Therapy for the Treatment of Recurrent, Metastatic Cervical Cancer: A Single-Arm, Open-Label, Phase II Study	Qin Xu (Fuzhou, China)
微芯生物	西达本胺	HDAC	乳腺癌	上市	368P	Poster	Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer afer CDK4/6 inhibioios preliminary findings of a multi-center, phase 2 study	Qiufan Zheng (Guangzhou, China)

# 标题概览-ESMO 2024 国产已上市产品

- 安罗替尼：通过联合疗法强力夯实市场地位

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
先声药业	曲拉西利	CDK4/6	晚期NSCLC	上市	1369P	Poster	Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: a prospective, single-arm, phase II clinical trial	Shen Cun Fang (Nanjing, China)
先声药业	恩沃利单抗	PD-L1	胆道癌	上市	53P	Poster	Envafohimab and Chidamide in combination with GEMOX as first-line treatment for advanced and metastatic biliary tract cancer (B-Enefits/SCOG-B001): A single-arm, exploratory, phase 2 trial: Interim report	Wei Li (Suzhou, China)
亚盛医药	奥雷巴替尼	BCR-ABL	SDH缺陷GIST	上市	1722MO	口头报告	Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)	Haibo Qiu (Guangzhou, China)
正大天晴	安罗替尼	VEGF	高级别神经胶质瘤	上市	447MO	口头报告	A Clinical Study of the Safety and Efficacy of Anlotinib Hydrochloride Combined with Temozolomide dose density scheme for the Treatment of Recurrent High Grade Glioma	Liang Wang (Xi'an, China)
正大天晴	安罗替尼+免疫	VEGF+PD-(L)0	GBM	上市	448MO	口头报告	A Clinical Study of the Safety and Efficacy of Toripalimab in Combination with Anlotinib for the Treatment of Recurrent Glioblastoma (GBM)	Liang Wang (Xi'an, China)
正大天晴	安罗替尼+免疫	VEGF+PD-(L)1	NSCLC围术期	上市	1239TiP	Poster	Neoadjuvant Hypofractionated Radiotherapy plus Tislelizumab with Anlotinib Followed by Adjuvant Tislelizumab with Anlotinib in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Trial in Progress	Min Fang (Hangzhou, China)
正大天晴	安罗替尼+免疫	VEGF+PD-(L)1	软组织肉瘤	上市	1735P	Poster	Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): a single-centre, single-arm, phase 2 trial	Zengjun Liu (Jinan, China)
正大天晴	安罗替尼+免疫	VEGF+PD-(L)1	TNBC	上市	389P	Poster	Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial	Huihui Li (Jinan, China, Shandong)
正大天晴	安罗替尼+免疫	VEGF+PD-(L)1	软组织肉瘤	上市	1748P	Poster	A prospective, phase II study of Tislelizumab administered in combination with Eribulin and Anlotinib for patients (pts) with advanced adult Soft Tissue Sarcoma (TEASTS)	Xi Guo (Shanghai, China)
正大天晴	贝莫苏拜单抗+安罗替尼	VEGF+PD-(L)1	HCC辅助	上市	949P	Poster	Update results of ALTER-H006: a phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection	Xianhai Mao (Changsha, China)
正大天晴	安罗替尼+曲美替尼	VEGF+KRAS/MEK	non-G12C KRAS-mutant NSCLC	上市	1306P	Poster	Trametinib plus Anlotinib in non-G12C KRAS-mutant Non-Small Cell Lung Cancer: a single-center, open-label, single-cohort study	Baohui Han (Shanghai, China)
正大天晴	安罗替尼+T-DXd	VEGF+HER2 ADC	HER2-Low BC	上市	434TiP	Poster	ALTER-BC-1b-01: a Prospective Phase Ib Study of Anlotinib with Trastuzumab Deruxtecan (T-DXd) for HER2-Low Unresectable (u)/Metastatic (m) Breast Cancer (BC)	Yanchun Meng (Shanghai, China)

数据来源：ESMO官网，中泰证券研究所

# 标题概览-WCLC 2024 国产已上市产品

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
艾力斯	伏美替尼	三代EGFR	NSCLC辅助IA-IB	上市	MA15.12	口头报告	Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations.	R. Geng (Peking Union Medical College Hospital)
艾力斯	伏美替尼	三代EGFR	NSCLC一线	上市	EP.12A.08	poster	Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study.	N.n. Yan (The First Affiliated Hospital of Zhengzhou University)
艾力斯	伏美替尼	三代EGFR	NSCLC辅助IB-IIA	上市	P4.07D.02	poster	Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC with High-Risk Pathological Factors.	X-L. Li (Shanghai General Hospital)
艾力斯	伏美替尼+埃克替尼	三代+一代EGFR	一线L858R和脑转移NSCLC	上市	P3.12D.05	poster	Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups.	H. Chen (Affiliated Hospital of Guangdong Medical University)
艾力斯	伏美替尼	三代EGFR	未经TKI治疗EGFR PACC突变NSCLC	上市	PL04.07	主席研讨	FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations	
贝达药业	恩沙替尼	ALK抑制剂	一线ALK突变NSCLC	上市	MA06.04	口头报告	Unecritinib in Patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer: Updated Results from a Phase II Trial	Z. Li (Shanghai Chest Hospital)
百济神州	替雷利珠单抗	PD-1	胸腺癌	上市	MA05.03	口头报告	A Phase II Study of Tislelizumab Combined with Chemotherapy in Patients with Thymic Carcinoma	L. Wu, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha/CN
百济神州	替雷利珠单抗	PD-1	Stage IIB-IIIC NSCLC围术期	上市	P1.08C.03	poster	Updated Event-Free Survival of Tislelizumab Plus Chemotherapy Asneoadjuvant/Adjuvant Therapy for Stage IIB-IIIC NSCLC (LungMark Study)	Y-B. Lin, Sun Yat-Sen University Cancer Center, Guangzhou/CN
百济神州	替雷利珠单抗	PD-1	NSCLC新辅助	上市	EP.08D.09	poster	Efficacy and Safety of Neoadjuvant Tislelizumab Plus Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: a Pooled Analysis	Y-B. Lin, Sun Yat-Sen University Cancer Center, Guangzhou/CN
复宏汉霖	斯鲁利单抗	PD-1	ES-SCLC	上市	P1.13A.07	poster	Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study	L. Wu
翰森制药	阿美替尼	EGFR-TKI	stage III NSCLC化疗后维持治疗	上市	PL04.13	主席研讨	Aumolertinib Maintenance after Chemoradiotherapy in stage III Non-Small-Cell Lung Cancer: Interim Results of the phase III study (POLESTAR)	J. Yu
翰森制药	阿美替尼	EGFR-TKI	I-III EGFR-Mutant NSCLC	上市	MA15.11	口头报告	Aumolertinib as Adjuvant Therapy in Resectable I-III EGFR-Mutant NSCLC : Also Effective in Patients with High-Risk Relapse Factors	J. Yao (Jilin Province People's Hospital)
翰森制药	阿美替尼	EGFR-TKI	Stage I EGFR-Mutated NSCLC	上市	EP.07C.04	poster	Adjuvant Aumolertinib in Resected Stage I EGFR-Mutated NSCLC: Prospectively Evaluating Efficacy in Residual GGN Lesions	C.B. Huang
翰森制药	阿美替尼	EGFR-TKI	Stage IB-IIIA NSCLC	上市	EP.07C.05	poster	Efficacy and Safety of Aumolertinib in Stage IB-IIIA NSCLC after R0 Resection and the Correlation Between Efficacy and Postoperative MRD Status	S. Yang
翰森制药	阿美替尼	EGFR-TKI	EGFR M+ NSCLC新辅助	上市	EP.07C.13	poster	Aumolertinib as Neoadjuvant Therapy for EGFR M+ NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated	Q. Wu
翰森制药	阿美替尼	EGFR-TKI	EGFR M+ NSCLC辅助	上市	EP.08D.08	poster	Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors	Y.Y. Wang, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai/CN

# 标题概览-WCLC 2024 国产已上市产品

- 依沃西单抗：头对头K药研究入选主席研讨，此外将发布线数前移研究

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
翰森制药	阿美替尼	EGFR-TKI	EGFR-Mutant NSCLC	上市	EP.08F.03	poster	Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study	X. MENG, Shandong Cancer Hospital and Institute Shandong First Medical University, JINAN/CN
翰森制药	阿美替尼	EGFR-TKI	1L脑转EGFR-Mutant NSCLC	上市	P1.12A.05	poster	Aumolertinib in Treatment-Naive EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY	X. Zhang, The affiliated hospital of Zhengzhou university, Henan Cancer Hospital, Zhengzhou/CN
翰森制药	阿美替尼	EGFR-TKI	1L NSCLC脑转移	上市	EP.12A.22	poster	Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study.	J. Xu (he First Affiliated Hospital of Nanjing Medical University)
翰森制药	阿美替尼	EGFR-TKI	EGFR M+ NSCLC辅助	上市	EP.07E.07	poster	Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIa Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations	Q. Zhang
恒瑞医药	卡瑞利珠单抗	PD-1	NSCLC新辅助	上市	MA01.05	口头报告	Efficacy and Safety of Neoadjuvant Camrelizumab and Apatinib Combined with Chemotherapy in Stage IIIA (N2) NSCLC: A Single Arm, Phase II Trial	L. Zhao(Shengli Clinical Medical College of Fujian Medical University, Fuzhou/CN)
和黄医药	索凡替尼	VEGFR	远端转移小细胞肺癌	上市	EP.13A.04	poster	A Study of Surufatinib Combined with Low Dose Topotecan in Second or Third-Line Multiple Distant Organ Metastatic ES-SCLC.	Y. Du (The First Affiliated Hospital of Anhui Medical University)
和黄医药	赛沃替尼+奥希替尼	MET抑制剂	1L原发MET Aberrant, EGFRm NSCLC	上市	PL04.10	主席研讨	Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial	J. Yang
和黄医药	赛沃替尼	MET抑制剂	MET+EGFR野生型NSCLC	上市	EP.12A.38	poster	Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series.	J. Liu (Guangdong Provincial People's Hospital)
和黄医药	赛沃替尼	MET抑制剂	MET+NSCLC一线	上市	EP.12D.07	poster	Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series.	X. Li (Beijing Tiantan Hospital)
和黄医药	赛沃替尼+奥希替尼	MET抑制剂+EGFR抑制剂	EGFRm/MET+NSCLC	上市	EP.12A.40	poster	Savolitinib Plus Osimertinib for Previously Untreated NSCLC Patients with EGFR Mutations and Met-Amplification: A Case Series.	K. Xiao (The Second Xiangya Hospital)
和黄医药	赛沃替尼+三代EGFR	MET抑制剂+EGFR抑制剂	EGFRm/MET+NSCLC	上市	EP.12A.43	poster	Savolitinib and Third-Generation EGFR-TKI Therapy in EGFRm, MET-Altered NSCLC Patients: A Case Series.	X. Lai (The First Affiliated Hospital of Wenzhou Medical University)
君实生物	特瑞普利单抗	PD-1	IIB-IIIb NSCLC	上市	P1.03D.01	poster	Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIb Non-Small Cell Lung Cancer (NSCLC).	N. Wu (Peking University Cancer Hospital)
康方生物	依沃西单抗	PD-1/VEGF	NSCLC	上市	PL02.04	主席研讨	Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONI-2	C. Zhou
康方生物	依沃西单抗	PD-1/VEGF	NSCLC	上市	OA01.04	口头报告	A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer.	X. Zhao (Tianjin Medical University Cancer Institute & Hospital)

# 标题概览-WCLC 2024 国产已上市产品

## ● 维迪西妥单抗：大适应症NSCLC海外site研究入选


公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
康方生物	卡度尼利单抗	PD-1/CTLA-4	NSCLC	上市	EP.11D.01	poster	A Phase II Study of Cadonilimab Plus Chemotherapy as First-Line Treatment for PD-L1-Negative Advanced Non-Small Cell Lung Cancer:LungCadX	L. Wang (Shanghai Pulmonary Hospital & Thoracic Cancer Institute)
康方生物	卡度尼利单抗	PD-1/CTLA-4	NSCLC	上市	EP.07C.02	poster	Perioperative Cadonilimab and Chemotherapy in Stage II-III Non-Small-Cell Lung Cancer: Preliminary Results from a Phase II Study.	H. Wang (the Affiliated Cancer Hospital of Zhengzhou University)
康方生物	卡度尼利单抗	PD-1/CTLA-4	胸膜间皮瘤	上市	EP.14D.01	poster	Cadonilimab Plus Bevacizumab and Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma: A Single-Arm Phase II Study.	w. fang (Sun Yat-sen University Cancer Center)
荣昌生物	维迪西妥单抗	HER2 ADC	HER2表达NSCLC	上市	P2.10A.01	poster	Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress).	J. Riess (UC Davis Comprehensive Cancer Center)
荣昌生物	维迪西妥单抗+替雷利珠单抗	HER2 ADC+PD-1	HER2改变NSCLC	上市	P2.10A.03	poster	RESOLUTION: Phase II Study of Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in Patients with HER2 Alteration Advanced NSCLC.	J. Chen (Shanghai Pulmonary Hospital, Shanghai)
信达生物	信迪利单抗	PD-1	NSCLC	上市	P4.11E.10	poster	Safety and Efficacy of Sintilimab Combined with Anlotinib in Patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer.	F. Wang (Peking University Shenzhen Hospital)
先声药业	曲拉西利	CDK4/6	一线肺鳞癌	上市	P4.11E.05	poster	A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC.	Y. Wang (West China Hospital, Sichuan University)
正大天晴	安奈克替尼	ALK/ROS1/c-MET	ROS1+NSCLC	上市	MA06.04	口头报告	Unecritinib in Patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer: Updated Results from a Phase II Trial	S. Lu, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai/CN
正大天晴	贝莫苏拜单抗+安罗替尼	PD-L1+VEGF	EGFR TKI经治NSCLC	上市	MA11.10	口头报告	Benmelstobart, a PD-L1 Mab, Plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies:Phase II Results Update	M. Shi, Jiangsu Cancer Hospital, Nanjing, Jiangsu Province/CN
正大天晴	安罗替尼+药	PD-L1+VEGF	ES-SCLC维持治疗	上市	MA17.07	口头报告	Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial	B. Han
正大天晴	安罗替尼+替雷利珠单抗	PD-1+VEGF	2L ES-SCLC	上市	MA17.09	口头报告	Efficacy and Safety of Tislelizumab Plus Anlotinib and 2-Cycle Irinotecan as Second-Line Treatment for ES-Small Cell Lung Cancer(ESTAIL)	x. chen
正大天晴	安罗替尼+EGFR TKI	VEGFR+EGFR	EGFR TKI辅助经治局部进展NSCLC	上市	EP.07E.05	poster	Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs	T. Thamrongjirapat
正大天晴	安罗替尼	VEGF	免疫检查点抑制剂治疗后NSCLC	上市	EP.13B.08	poster	Enhanced Efficacy of Anlotinib in Small Cell Lung Cancer after Immune Checkpoint Inhibitor Exposure	J. Shan

# 重点关注：AK112-NSCLC线数前移，或将更新头对头K药数据

AK112 在 EGFR TKI 耐药 NSCLC 实现与国内主要在研疗法可比的疗效

AK112 在 1L PD-L1+NSCLC 疗效明显优于K药单药及联合雷莫芦单抗（非头对头）

药品名称	AK112		替雷利珠单抗	BL-B01D1	SKB264	信迪利单抗	
企业	康方生物		百济神州	百利天恒	科伦博泰	信达药业	
最高阶段	已上市		-	III期	III期	已上市	
已读出数据临床试验	AK112-201, NCT04736823 (2024 ELCC更新)	AK112-201, NCT04736823 (eClinicalMedicine 2023年8月发表)	HARMONI-A	NCT04310943 (IIT 研究)	NCT05194982	KL264-01	ORIENT-31
试验设计与基线	队列 2: EGFR-TKI进展的EGFR突变的晚期非鳞NSCLC, 26.3%一代/二代耐药, 73.7%一代/二代耐药后三代耐药, 使用AK112+化疗		AK112+化疗 vs 安慰剂+化疗, 86.3% versus 85.1%使用过三代EGFR TKI, 21.7% versus 23.0%脑转移	EGFR-TKI进展的EGFR突变的晚期NSCLC, 71.4%一代/二代耐药后三代耐药, 使用替雷利珠单抗+贝伐珠单抗+化疗	EGFR-TKI进展的EGFR突变的晚期NSCLC, 88%三代耐药, 使用BL-B01D1单药	EGFR-TKI进展的EGFR突变的晚期NSCLC, 50%亦化疗耐药, 使用SKB264单药	EGFR-TKI进展的EGFR突变的晚期NSCLC, 39% vs 34% vs 37%使用过三代EGFR TKI, 信迪利单抗+贝伐珠单抗+化疗 vs 信迪利单抗+化疗 vs 化疗
例数 (单臂/实验组 vs 对照组)	19		161 vs 161进入随机化		34	158 vs 158 vs 160	
有效性数据 (单臂/实验组 vs 对照组)	中位随访时间为25.8个月 ORR为68.4% DCR为94.7% mDoR为8.7个月; mPFS为8.5个月, mOS达22.5个月, 12个月OS率约73.7%	中位随访时间为11.0个月 ORR为68.4% DCR为94.7% mDoR为8.38个月; mPFS为8.5个月, 12个月PFS率约35.5%	mPFS=7.06m versus 4.80m, HR=0.46, 三代EGFR TKI经治、脑转移亚组mPFS均有延长, 分别HR=0.48, HR=0.4	中位随访时间为11.2个月 ORR=66.7% DCR为100% mDOR为5.3个月	ORR=61.8% DCR为91.2%	中位随访时间为17.2个月 ORR=60% mDOR为8.7个月, mPFS为11.5个月, mOS达22.7个月, 12个月OS率约81%, 18个月OS率为76.2%	mPFS=7.2月 (相对化疗HR=0.51) vs 5.5月 (相对化疗HR=0.72) vs 4.3月; mOS=21.1月 vs 20.5月 vs 19.2月 两线EGFR TKI经治、脑转移亚组mPFS分别HR=1.30, HR=0.84
安全性数据 (单臂/实验组 vs 对照组)	3级以上 TRAEs=26.5% (3个队列分析集, n=83)		≥3 TEAEs=61.5% versus 49.1%	3级以上 TEAEs=35.7%		3级以上 TRAEs=69.8% (包括EGFR野生, n=43)	≥3级TRAE=56% vs 41% vs 49%





3

# 海外重点产品及相关标的

# 标题概览-ESMO 2024 海外重点产品

- AZD8205: B7H4 ADC, 翰森曾授予GSK同类产品HS-20089全球独占许可 (不含大中华区), 百济则通过映恩生物引进同类产品全球权益
- ABBV-400: c-met ADC, 国内恒瑞医药、荣昌生物拥有同类品种处在临床早期阶段
- AMG 193: PRMT5抑制剂, 合成致死机制, 石药集团、先声药业有同类产品处在临床阶段
- ASP3082: KRAS G12D蛋白降解剂, 恒瑞医药的同靶点抑制剂曾在ESMO 2023读出初步临床数据

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
AZ	AZD5335	FR $\alpha$ ADC	PRROC	I/II 期	754P	Poster	Initial results from a first-in-human study of AZD5335, a folate receptor $\alpha$ (FR $\alpha$ )-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)	Ronnie Shapira-Frommer (Ramat Gan, Israel)
AZ	AZD8205	B7H4 ADC	实体瘤	I/II 期	606O	口头报告	Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatumab samrotectan) in patients with advanced/metastatic solid tumors	Funda Meric-Bernstam (Houston, United States of America, TX)
Ascendis	TransCon IL-2 $\beta/\gamma$	IL-2R激动剂	PROC	II期	762P	Poster	First Results from Phase 2 Dose Expansion Cohort of TransCon IL-2 $\beta/\gamma$ in Combination with Standard of Care Chemotherapy for Platinum Resistant Ovarian Cancer (PROC) in the IL Believe Trial	Oladapo Yeku (Boston, United States of America)
艾伯维	ABBV-400	c-Met ADC	NSCLC	I/II 期	1257MO	口头报告	ABBV-400, a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) With Advanced EGFR Wildtype (WT) Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC): Results From a Phase 1 Study	María De Miguel (Madrid, Spain)
艾伯维	ABBV-400	c-Met ADC	GEA	I/II 期	1439P	Poster	ABBV-400, a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC), in Patients (pts) With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (GEA): Results From a Phase 1 Study	John H. Strickler (Durham, United States of America)
艾伯维	ABBV-969	PSMA/STEAP1 ADC	mCRPC	I期	1660TiP	Poster	First-in-Human Study of ABBV-969, a Dual Variable Antibody-Drug Conjugate (ADC), in Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Raanan Berger (Ramat Gan, Israel)
安进	AMG 193	PRMT5 inhibitor	实体瘤	I/II 期	604O	口头报告	Phase 1 dose escalation and initial dose expansion results of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors	Adrian G. Sacher (Toronto, Canada)
安斯泰来	ASP3082	KRAS G12D蛋白降解剂	胰腺癌、结直肠癌、NSCLC	I期	608O	口头报告	Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)	Wungki Park (New York, United States of America)
Bristol Myers Squibb Co.	CC-94676 (BMS-986365)	AR降解	前列腺癌	I期	1597MO	口头报告	Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)	Dana Rathkopf (New York, United States of America, NY)
Bristol Myers Squibb Co.	BMS-986012 +CE/NIVO	Fuc-GM1 mAb+化疗+PD-1	ES-SCLC	II 期	1786MO	口头报告	BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase 2 study	Ewa Kalinka (Łódź, Poland)

## 标题概览-ESMO 2024 海外重点产品

- Bicycle入选了多项双环肽偶联毒素的研究
- Ziplertinib: 治疗埃万妥单抗经治NSCLC研究入选口头, 有望进一步展现WGFR exon 20抑制剂疗效
- CFT1946: BiDAC降解剂, 贝达曾以约4亿美元引进基于相同技术平台的BiDAC降解剂产品

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
Bicycle	BT7480	Nectin-4/CD137	实体瘤	I/II 期	650P	Poster	Initial results from a phase 1/2 study of BT7480, a novel Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors	Kyriakos P. Papadopoulos (San Antonio, United States of America, TX)
Bicycle	BT8009	Nectin-4 BTC	UC	I/II 期	652P	Poster	BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1	Oscar Reig Torras (Barcelona, Spain)
Bicycle	BT8009, BT5528	Nectin-4 BTC, EphA2 BTC	实体瘤	I/II 期	654P	Poster	Peripheral neuropathy (PN) following treatment (tx) with Bicycle Toxin Conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors	Bernard Doger de Spéville (Madrid, Spain)
Bicycle	BT5528	EphA2 BTC	实体瘤	I/II 期	647P	Poster	EphA2-targeting Bicycle Toxin Conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase 1/2 study	Elisa Fontana (London, United Kingdom, Surrey)
Cullinan (再鼎引进)	Ziplertinib	EGFR exon 20抑制剂	NSCLC	III 期	1254MO	口头报告	Safety and Antitumor Activity of Ziplertinib in NSCLC Patients (pts) with EGFR Exon 20 Insertion (ex20ins) Mutations Who Received Prior Amivantamab	Antonio Passaro (Milan, Italy)
Calliditas	Setanaxib	NOX1/4	复发或转移性头部鳞状细胞癌	III 期	853MO	口头报告	Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind Phase 2 trial	Jérôme Fayette (Lyon, France, CEDEX)
C4 Therapeutics	CFT1946	BRAF V600 BIDAC降解	实体瘤	I 期	612MO	口头报告	Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degradar in Mutant BRAF V600 Solid Tumors	Maria Vieito (Barcelona, Spain, La Coruña)

## 标题概览-ESMO 2024 海外重点产品

- T-DXD、Dato-Dxd: HER2 ADC、TROP2 ADC经典品种，适应症拓展情况、亚组分析情况象征国内相关产品市场前景，相关标的：荣昌生物、科伦博泰等
- 第一三共作为全球ADC技术平台领先的代表企业，HER3 ADC、CLDN6 ADC、B7H3 ADC的数据读出及更新情况具有行业里程碑意义，相关标的：百利天恒、恒瑞医药、翰森制药、信达生物、迈威生物等

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
第一三共	Trastuzumab deruxtecan	HER2 ADC	乳腺癌新辅助	已上市	317TiP	Poster	A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive breast cancer (ARIADNE)	Theodoros Foukakis (Stockholm, Sweden)
第一三共	Trastuzumab deruxtecan	HER2 ADC	HER2+食管、胃、胃食管连接处癌	已上市	1401O	口头报告	Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)	Yelena Y. Janjigian (New York, United States of America, NY)
第一三共	Trastuzumab deruxtecan	HER2 ADC	乳腺癌	已上市	343MO	口头报告	Unraveling the mechanisms of action and resistance to Trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial	Maria Fernanda Mosele
第一三共	Patritumab Deruxtecan	HER3 ADC	乳腺癌	III期	340O	口头报告	Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)	Barbara Pistilli (Villejuif, Cedex, France)
第一三共	DS-9606a	CLDN6 ADC	CLDN6+实体瘤	I/II 期	610O	口头报告	Preliminary results from a Phase 1, first-in-human study of DS-9606a, a Claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6	Manish R. Patel (Fort Myers, United States of America)
第一三共	Dato-DXd	TROP2 ADC	子宫内膜癌和卵巢癌	已上市	714MO	口头报告	Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the Phase 2 TROPION-PanTumor03 study	Ana Oaknin (Barcelona, Spain)
第一三共	Dato-DXd	TROP2 ADC	nsq-NSCLC带脑转	已上市	1312P	Poster	Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): results from TROPION-Lung01	Elvire Pons-Tostivint (Nantes, Cedex 1, France)
第一三共	I-DXd	B7H3 ADC	1L ES-SCLC	I/II 期	1812TiP	Poster	IDeate-Lung03: A Phase 1b/2 study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)	Charles M. Rudin (New York, United States of America)

# 标题概览-ESMO 2024 海外重点产品

- HST-1011: CBL-B为新兴靶点, 国内先声再明已布局同靶点产品
- PF-07220060+PF-07104091: CDK2联用CDK4数据, 百济曾重金引进CDK2产品
- Mirvetuximab Soravtansine: 全球首个上市的FR $\alpha$  ADC向铂敏感OC拓展

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
Eutilex (金斯瑞合作伙伴)	EU307	GPC3 CART	GPC3+ HCC	I 期	987TiP	Poster	First-in-Human Dose Escalation Trial of Fourth Generation Chimeric Antigen Receptor (CAR) T-cell therapy (EU307) in Patients with Glypican-3 (GPC3) Positive Hepatocellular Carcinoma (HCC)	Do-Young Kim (Seoul, Korea, Republic of)
HotSpot	HST-1011	CBL-B小分子变构抑制剂	晚期实体瘤	I 期	991O	口头报告	First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors	Rachel E. Sanborn (Portland, United States of America)
辉瑞	PF-07220060+PF-07104091	CDK4+CDK2	BC	I 期	618MO	口头报告	Phase 1b/2 first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors	Timothy Anthony Yap (Houston, United States of America, Surrey)
辉瑞	sigvotatug vedotin	ITGB6 ADC	NSCLC	I 期	1398TiP	Poster	Be6A Lung-01, a phase 3 study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)	Solange Peters (Lausanne, Switzerland)
Immunogen	Mirvetuximab Soravtansine	FR $\alpha$ ADC	FR $\alpha$ 高表达铂敏感卵巢癌	已上市	718MO	口头报告	Mirvetuximab Soravtansine (MIRV) in Recurrent Platinum-Sensitive Ovarian Cancer (PSOC) with High Folate Receptor-Alpha (FR $\alpha$ ) Expression: Results from the PICCOLO Trial	Angeles A. Secord (Durham, United States of America)
INCYTE	INCB123667	CDK2	晚期实体瘤	I 期	617MO	口头报告	Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (Pts) With Advanced Solid Tumors: A Phase 1 Study	Matteo Simonelli (Pieve Emanuele, Italy)
Kinnate	Exarafenib+Binimetinib	Pan-RAF +MEK 1/2	NRAS-mutant黑色素瘤, BRAF改变实体瘤	I 期	613MO	口头报告	A Phase 1 Clinical Trial Evaluating Exarafenib, a Selective Pan-RAF Inhibitor in Combination with Binimetinib in NRAS-mutant (NRASMut) Melanoma (Mel) & BRAF-Altered Solid Tumors	Philippe Cassier (Lyon, France)
Merck	M9140	CEACAM5 ADC	mCRC	I 期	573P	Poster	M9140, an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): updated results from a Phase 1 trial	Valentina Boni (Pozuelo de Alarcon, Spain)
NeolmmuneTech	NT-17 (efineptakin alfa)	IL-7, post-CD19-directed CART	DLBCL	I/II 期	806MO	口头报告	Phase 1b study of NT-17 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)	Armin Ghobadi (St. Louis, United States of America)
Nuvalent	NVL-655	第四代ALK	ALK+实体瘤	I/II 期	1253O	口头报告	Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors	Alexander E. Drilon (New York, United States of America, NY)

## 标题概览-ESMO 2024 海外重点产品

- SGN-PDL1V: 全球首个PD-L1 ADC, 相关标的: 复宏汉霖/复星医药
- Rezatapopt: 难以成药靶点, 加科思完成p53 Y220C激活剂首例患者给药
- Futibatinib: FGFR抑制剂治疗大癌种数据, 相关标的: 和誉医药

公司	药物	机制	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
PMV	Rezatapopt	p53	TP53 Y220C Mutation实体瘤	I/II 期	691TiP	Poster	PYNNACLE Phase 2 Trial of Rezatapopt (PC14586) in Solid Tumors with a TP53 Y220C Mutation	Alison M. Schram (New York, United States of America)
普方生物	Rina-S	FR $\alpha$ ADC	晚期卵巢癌或子宫内膜癌	I/II 期	719MO	口头报告	A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients with Advanced Ovarian or Endometrial Cancer	Elizabeth K. Lee (Boston, United States of America)
Prelude	PRT3789	SMARCA2降解	SMARCA4 Mut实体瘤	I期	603O	口头报告	First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degradar, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation	Robin Guo (New York, United States of America)
Sutro (天士力引进)	Luveltamab tazevibulin	FR $\alpha$ ADC	OC	III期	749P	Poster	Luveltamab tazevibulin, an antifolate receptor alpha (FR $\alpha$ ) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase 1 study	Lainie P. Martin (Philadelphia, United States of America, PA)
Seagen	SGN-PDL1V	PD-L1 ADC	PD-L1+实体瘤	I 期	607O	口头报告	Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors	Marc Oliva (Hospitalet de Llobregat, Spain)
TORL	TORL-1-23	CLDN6 ADC	晚期实体瘤	I 期	721MO	口头报告	Phase I, Two-Part, Multicenter First-In-Human (FIH) Study of TORL-1-23, A Novel Claudin 6 (CLDN6) Targeting Antibody Drug Conjugate (ADC) In Patient With Advanced Solid Tumors.	Gottfried E. Konecny (Los Angeles, United States of America, CA)
Taiho Oncology	futibatinib	FGFR1-4	mUC	已上市	1965MO	口头报告	Phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety	Vadim S. Koshkin (San Francisco, United States of America)
武田	TAK-676+K药	STING激动剂+PD-1	晚期实体瘤	I 期	996MO	口头报告	Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: data from phase 1 dose escalation	Jason J. Luke (Pittsburgh, United States of America)
Zymeworks (百济神州引进权益)	Zanidatamab	HER2双抗	1L CRC	III期	516P	Poster	Zanidatamab (Zani) + Chemotherapy (CT) in First-Line (1L) Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Colorectal Cancer (mCRC)	Sun Young Rha (Seoul, Korea, Republic of)

# 标题概览-WCLC 2024 海外重点产品

- N803: ASCO针对NSCLC的初步数据不及公司公告描述, 关注随访期拉长后的有效性表现, 相关标的: 奥赛康

公司	药物	靶点	癌种	药物最高开发阶段	摘要号	交流形式	题目	PI/一作
AZ	Durvalumab+ Novel Anticancer Agents	PD-L1	NSCLC围手术期	上市	PL02.07	主席研讨	Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC	T. Cascone
BI	Zongertinib	HER2小分子	HER2+ NSCLC	III期	PL04.04	主席研讨	Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC	G. Ruiter
BI	Zongertinib	HER2小分子	HER2+实体瘤带脑转	III期	MA12.10	口头报告	Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial	F. Opdam
Bayer	BAY2927088	EGFR、HER2抑制剂	HER2m NSCLC	III期	PL04.03	主席研讨	Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study	X. Le
葆元医药 (信达引进)	Taletrectinib	ROS1/NTRK	ROS1+NSCLC	II期	MA06.04	口头报告	Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study	G. Liu, Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto/ON/CA
第一三共	Ifinatamab Deruxtecan	B7H3 ADC	ES-SCLC	III期	OA04.03	口头报告	Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01	C.M. Rudin
Gilead	Sacituzumab Govitecan	TROP2 ADC	2L ES-SCLC	上市	OA04.04	口头报告	Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer	A. Dowlati
Gilead	Sacituzumab Govitecan	TROP-2 ADC	晚期NSCLC	上市	OA08.06	口头报告	Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01	M.C. Garassino (University of Chicago Comprehensive Cancer Center)
immunitybio	N-803+CPI	IL15+PD-(L)1	2L+ NSCLC	上市	OA06.05	口头报告	IL15 Superagonist (N-803, Anktiva) + Checkpoint Inhibitor (CPI) Prolongs OS in 2ndline or Greater NSCLC Patients Failing CPI	J. wrangle,MUSC, Charleston/SC/USA
J INTS BIO	JIN-A02	4代EGFR	EGFRm NSCLC	I/II期	P3.12D.02	poster	Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutated Advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)	S.M. Lim



4

# 风险提示

# 风险提示

1 商业化不及预期风险

2 临床开发进度不及预期风险

3 研究报告使用的公开资料可能存在信息滞后或更新不及时的风险：报告中部分内容来自于公开资料，可能存在公开资料信息滞后或更新不及时的风险；第三方数据失真风险。

## 重要声明

- **中泰证券股份有限公司（以下简称“本公司”）具有中国证券监督管理委员会许可的证券投资咨询业务资格。本报告仅供本公司的客户使用。本公司不会因接收人收到本报告而视其为客户。**
- 本报告基于本公司及其研究人员认为可信的公开资料或实地调研资料，反映了作者的研究观点，力求独立、客观和公正，结论不受任何第三方的授意或影响。本公司力求但不保证这些信息的准确性和完整性，且本报告中的资料、意见、预测均反映报告初次公开发布时的判断，可能会随时调整。本公司对本报告所含信息可在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。本报告所载的资料、工具、意见、信息及推测只提供给客户作参考之用，不构成任何投资、法律、会计或税务的最终操作建议，本公司不就报告中的内容对最终操作建议做出任何担保。本报告中所指的投资及服务可能不适合个别客户，不构成客户私人咨询建议。
- 市场有风险，投资需谨慎。在任何情况下，本公司不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。
- 投资者应注意，在法律允许的情况下，本公司及其本公司的关联机构可能会持有报告中涉及的公司所发行的证券并进行交易，并可能为这些公司正在提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。本公司及其本公司的关联机构或个人可能在本报告公开发布之前已经使用或了解其中的信息。
- 本报告版权归“中泰证券股份有限公司”所有。事先未经本公司书面授权，任何机构和个人，不得对本报告进行任何形式的翻版、发布、复制、转载、刊登、篡改，且不得对本报告进行有悖原意的删节或修改